For children, adolescents, and adults with hemophilia B
EXPERIENCE LONG-LASTING
BLEED PROTECTIONWITH THE STRENGTH OF IDELVION
ONLY IDELVION DELIVERS
High and sustained
Factor IX levels in clinical trials
in adolescents and adults
FACTOR IX LEVELS
Patients who started and stayed on prophylaxis prove IDELVION has powerful efficacy with both 7- and 14-day dosing*
UNCOVERIDELVION'S EFFICACY
*Of the 23 subjects in Arm 2, 19 were transitioned from on-demand to 7-day prophylaxis. The median AsBR during prophylaxis treatment was 0.7 (range: 0 to 4.2). Data for Arms 1 and 2 based on matched-pairs design.
†Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
IDELVION keeps up with the changing needs of your patients as they grow.2-6
Children: 7-day dosing (40-55 IU/kg). Adults and adolescents (in patients 12 years or older): Start on 7-day dosing (25-40 IU/kg). Once well-controlled*, extend to 14-day dosing (50-75 IU/kg).
LONGEST SINGLE-DOSE HALF-LIFE:
CHILDREN: 90-93 HOURS | ADOLESCENTS AND ADULTS: 104 HOURS
*Once well‑controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.
Resources for your patients through IDELVION ConnectSM
MOST PATIENTS
WITH COMMERCIAL
INSURANCE PAY
The Copay support program helps eligible patients with commercial insurance by assisting with out-of-pocket expenses for IDELVION. Most people with commercial insurance pay $0 out-of-pocket.
CSL Behring is committed to providing treatment and support services that make a meaningful difference in the lives of people with bleeding disorders.
Resources are available to help your eligible patients get the treatment they need for hemophilia B, including:
- A free trial of IDELVION
- Co-pay assistance‡
- Support in event of lapse in coverage with the CSL Behring AssuranceSM program§
- Reimbursement and access support
‡Subject to terms and conditions of the co-pay assistance program. To read the full terms and conditions, click here. CSL Behring reserves the right to rescind, revoke, or amend the program at any time without notice.
§Terms, conditions, and limitations apply. Visit here to view terms and conditions.
References: 1. Data on file. Available from CSL Behring as DOF IDL-006. 2. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735. 3. Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016;127(14):1761-1769. doi:10.1182/blood-2015-09-669234. 4. Data on file. Available from CSL Behring as DOF IDL-009.
Have additional questions?
Connect with CSL Behring Medical Affairs to
find additional information and ask questions.